Therapeutic options shown on this site are based on EMA drug approvals. Availability of drugs may vary in your country.
What services are provided by the Lung-Carcinoma-Portal?
Qualitätssicherungs-Initiative Pathologie GmbH (QuIP) was established with the aim of providing support services to pathologists in Germany and Europe, optimizing their testing results, and offering assistance for all of the relevant scientific and organizational activities required for quality assurance work. The Lung-Carcinoma-Portal was set up to offer pathologists, consultants working in other disciplines, and oncologists orientation at the interface between biomarker tests and therapy options. The Portal hosts a biomarker-based therapy algorithm for the diagnosis of lung carcinoma. This algorithm is based both on current medical guideline recommendations as well as the latest scientific findings, and provides full details of the underlying investigations.
References and citations on the Portal
The underlying sources from the research literature consulted by the portal content authors are cited as a list on a separate “References” tab on each of the relevant algorithm pages. In each case, these research references and citations reflect the current state of progress on the part of the scientific experts, and will be updated/amended regularly by the team as necessary.
Please note: While we have taken the greatest of care in preparing the information provided on our Lung-Carcinoma-Portal, we cannot accept any liability for the completeness, accuracy, and/or how current the information provided is. This applies in particular to third-party content made available on our website through the links we have provided. Please consult the summary of product characteristics for each drug compound to obtain current and/or further information.
Please also note that the material discussed here is generally characterized by the fact that pathologists may not necessarily agree on the specific details of an interpretation of the same set of images. We therefore always state the underlying data set on which the evaluation of the section is based in the reference sections. You bear sole responsibility for the evaluation of your own slides. Please contact us if you have any questions.
Qualitätssicherungs-Initiative Pathologie GmbH
QuIP is supported by AMGEN, AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, Lilly, Merck Serono and MSD Sharp & Dohme.